Back to Results
First PageMeta Content
Boehringer Ingelheim / Pharmacy / Respimat / Dabigatran / Pharmaceutical industry / Tiotropium bromide / Chronic / Chemistry / Organic chemistry / Medicine


KEY ASPECTS 2014  Andreas Barner, Wolfgang Baiker, Allan Hillgrove, Joachim Hasenmaier, Hubertus von Baumbach (from left to right), the Board of Managing Directors KEY ASPECTS 2014
Add to Reading List

Document Date: 2015-04-16 05:31:57

Open Document

File Size: 115,45 KB

Share Result on Facebook

City

Ingelheim / /

Company

Ben Venue Laboratories Inc. / Managing Directors KEY / /

Continent

Europe / /

Country

Germany / United States / /

Currency

EUR / /

Event

M&A / /

IndustryTerm

manufacturing facility / treatment of high blood pressure / healthcare system / pharmaceutical industry / combination product / authorisation applications / treatment of the rare disease / insurance industry / forward looking technologies / /

MedicalCondition

cuts / Alzheimer’s disease / severe psoriasis / COPD / schizophrenia / idiopathic pulmonary fibrosis / chronic obstructive pulmonary disease / rare disease / advanced lung cancer / Crohn’s disease / diabetes / psychiatric disorders / diseases / cardiometabolic diseases / chronic inflammatory bowel disease / pulmonary embolism / atrial fibrillation / inflammatory disease / spondylarthritis / high blood pressure / respiratory diseases / deep-vein thrombosis / asthma / /

MedicalTreatment

chemotherapy / /

Organization

US Food and Drug Administration / Board of Managing Directors KEY ASPECTS / /

Person

Joachim Hasenmaier / Wolfgang Baiker / Andreas Barner / Allan Hillgrove / /

Product

spiriva / micardis / /

Technology

forward looking technologies / chemotherapy / /

SocialTag